Objective: To evaluate the risk and pattern of multimorbidity in patients with sarcoidosis. Patients and Methods: A cohort of all residents of Olmsted County, Minnesota, first diagnosed with sarcoidosis between January 1, 1976, and December 31, 2013, was identified through the medical record linkage system of the Rochester Epidemiology Project. Diagnosis was verified by individual medical record review. A cohort of sex-and age-matched comparators without sarcoidosis was assembled from the same population. Data on 18 chronic conditions recommended by the US Department of Health and Human Services for both cases and comparators were retrieved and compared. Results: The prevalence of multimorbidity (ie, the presence of !2 chronic conditions) was similar between the 2 groups: 111 of 345 cases (32.2%) and 110 of 345 comparators (31.9%) (P¼.99). After the index date, 156 cases (43.8%) and 142 comparators (41.2%) developed multimorbidity, corresponding to a hazard ratio of 1.60 (95% CI, 1.27-2.01; P<.001). The cumulative incidence of the presence of !3, 4, and 5 chronic conditions was also consistently significantly higher in cases than in comparators (P value¼.01, .004 and .002, respectively). Analysis by specific type of chronic condition revealed a significantly higher cumulative incidence of coronary artery disease, congestive heart failure, arrhythmia, stroke or transient ischemic attack, arthritis, depression, diabetes, and major osteoporotic fracture. Conclusion: In this population, patients with sarcoidosis had a significantly higher risk of developing multimorbidity than did sex-and age-matched individuals without sarcoidosis.
1
The concept of multimorbidity is slightly different from the concept of comorbidity. In the traditional comorbidity model, an index disease is defined and is generally considered as the most important entity and studies of comorbidity generally focus on the cooccurrence of any additional disease entities and their effect on the treatment/prognosis of the index disease. In contrast, the concept of multimorbidity is more patient-centric with all morbidities regarded as of equal importance. Studies of multimorbidity usually put more emphasis on function and well-being of patients as a result of all morbidities. 1, 2 Comorbidity has long been a focus of epidemiological studies of immune-mediated diseases. The incidence of several comorbidities, particularly cardiovascular diseases, is increased in different immune-mediated diseases such as rheumatoid arthritis, systemic lupus erythematosus, vasculitis, and psoriasis. [3] [4] [5] [6] [7] [8] More recently, attention has also turned to multimorbidity in patients with immunemediated diseases, especially rheumatoid arthritis. 2, 9 There is more limited understanding of the extent and influence of multimorbidity in patients with other diseases, including sarcoidosis. The present study used a previously identified population-based cohort of patients with sarcoidosis to describe the occurrence of multimorbidity compared with persons without sarcoidosis randomly selected from the same underlying population.
between January 1, 1976 , and December 31, 2013, which was identified through the resources of the Rochester Epidemiology Project (REP). 10 The REP is a unique medical record linkage system that provides complete access to inpatient and outpatient medical records of all residents of Olmsted County, Minnesota, for more than 6 decades from all local health care providers, which include Mayo Clinic, the Olmsted Medical Center and its affiliated hospitals, local nursing homes, and the few private practitioners. The history and utility of the REP for epidemiological investigations have been described in detail elsewhere. 11 This cohort of patients with sarcoidosis was initially identified from diagnostic codes related to sarcoidosis and noncaseating granuloma and was confirmed by individual medical record review, which required physician diagnosis of sarcoidosis supported by the presence of noncaseating granuloma on biopsy, radiographic evidence of intrathoracic sarcoidosis, and compatible clinical manifestations, after exclusion of other granulomatous diseases such as tuberculosis and fungal infection. The only exception for the histopathological requirement was stage I pulmonary sarcoidosis that required only the evidence of symmetric bilateral hilar adenopathy on imaging. Isolated extrathoracic sarcoidosis of a specific organ without intrathoracic sarcoidosis was included (except for isolated cutaneous disease) if there was no better alternative diagnosis for the presence of noncaseating granuloma. 12 Isolated cutaneous disease was not included as it could be mimicked by several conditions, including cutaneous foreign body reaction, resulting in over-ascertainment of cases in the face of diagnostic uncertainty. Patients diagnosed with sarcoidosis before residency in Olmsted County (ie, prevalent cases) were excluded.
A cohort of sex-and age (within 3 years)e matched comparators without sarcoidosis at the time of the patient's sarcoidosis diagnosis was randomly selected from the same underlying population in a 1:1 ratio. Data on 20 chronic conditions recommended by the US Department of Health and Human Services 13 for both cases and comparators were retrieved electronically from the diagnostic codes in the REP medical record linkage system. However, 2 chronic conditions recommended by the US Department of Health and Human Services (ie, human immunodeficiency virus infections and autism spectrum disorders) were excluded from the analysis because of their rarity in this population. Diagnosis of the remaining 18 chronic conditions was made on the basis of the presence of these diagnostic codes within a category at least twice (and separated by at least 30 days) except for selected conditions that were collected by manual medical record review. These included physician diagnoses of congestive heart failure (CHF), coronary artery disease (CAD), stroke, transient ischemic attack, osteoporotic fracture, and/or hepatitis occurring at any time, either before or after the index date, as well as hypertension, hyperlipidemia, and diabetes mellitus diagnosed before the index date. 14, 15 Similarly, diagnosis of cancer was confirmed with Mayo Clinic's cancer registry, which continuously collects data on every type of malignancy except for nonmelanoma skin cancer. 16 Data on the use of glucocorticoids, diseasemodifying antirheumatic agents, and biological agents after sarcoidosis diagnosis were collected from cases.
Approval for this study was obtained from the Mayo Clinic and the Olmsted Medical Center institutional review boards (Mayo Clinic Institutional Review Board 14-008651; Olmsted Medical Center Institutional Review Board 012-OMC-15). The need for informed consent was waived.
Descriptive statistics (percentage, mean, etc) were used to summarize the characteristics of cases and comparators as well as the prevalence of each chronic condition at the incidence/index date. Comparisons between the cohorts were performed using chi-square, Fisher exact, and rank-sum tests. The cumulative incidence of the each chronic condition adjusted for the competing risk of death was estimated. 17 These methods are similar to the Kaplan-Meier method with censoring of patients who are still alive at last follow-up. However, patients who die before experiencing a chronic condition are appropriately accounted for to avoid overestimation of the rate of occurrence of the chronic condition, which can occur if such individuals are simply censored at death. For each chronic condition, patients whose diagnosis was before the diagnosis of sarcoidosis, or for individuals in the comparison cohort, before the index date, were excluded from the analysis of cumulative incidence. The date of occurrence of each of the combinations of multiple chronic conditions was the earliest date of occurrence of the specified number of individual conditions. For the accumulation of chronic conditions, Aalen-Johansen (a multistate generalization of cumulative incidence) methods were used to estimate the cumulative occurrence of multiple chronic conditions over time. Chronic conditions that were diagnosed before the index date were included in the analyses of the probability of experiencing 2, 3, 4, or !5 chronic conditions presented in Figure 1 .
Cox proportional hazards models were used to compare the rate of development of each chronic condition and the accumulation of multiple chronic conditions between patients with sarcoidosis and nonsarcoidosis comparators. Comparisons between cohorts of chronic conditions in the first years after the incidence/index date were performed by truncating follow-up at 5 years. Comparisons between cohorts of chronic conditions after the first years of follow-up were performed in those with at least 5 years of follow-up by beginning follow-up at 5 years. The 5-year cutoff point was chosen a priori as the highest disease activity and most of the medication use occurs during the first 5 years after the diagnosis of sarcoidosis. The proportional hazards assumption was checked, and no evidence of violation was found. A P value of less than .05 was considered statistically significant for all analyses. Analyses were performed using SAS version 9.4 (SAS Institute) and R 3.1.1 (R Foundation for Statistical Computing).
RESULTS
The sarcoidosis cohort consisted of 345 patients first diagnosed with sarcoidosis between 1976 and 2013 (mean age, 45.6 years; 50% women; 90% white; 5% African American). The comparator cohort included 345 ageand sex-matched persons from the same population (mean age, 45.4 years; 50% women; 95% white; 1% African American). The baseline characteristics of the individuals in this study are summarized in Table 1 . There was a notable difference in baseline characteristics between the 2 groups, specifically obesity and smoking status. The median length of follow-up was 12.9 years for cases and 15.6 years for comparators. In cases, oral glucocorticoids were the most commonly prescribed drug (113 cases; 32.8%) followed by hydroxychloroquine (13 cases; 3.8%), methotrexate (11 cases; 3.2%), other disease-modifying antirheumatic agents (5 cases; 1.4%), tumor necrosis factor inhibitor (5 cases; 1.4%), and other biological agents (4 cases; 1.2%). A total of 76 patients (22.0%) were exposed to comorbidities (inclusive of the probability at the index date) according to years after the sarcoidosis incidence/index date for patients with sarcoidosis (S) and comparators (C). Probability at year 0 is the probability at the index date (or prevalence at the index date). 
Prevalence and Incidence of Individual Comorbidity
The prevalence of individual comorbidity at the index date was not significantly different between the 2 groups, except for the significantly higher prevalence of arrhythmia in patients with sarcoidosis. In contrast, a significantly higher cumulative incidence at 10 years in patients with sarcoidosis was observed for several comorbidities including CHF, CAD, arrhythmia, stroke or transient ischemic attack, arthritis, depression, diabetes, and major osteoporotic fracture. Further adjustment for baseline variables (smoking status and obesity) yielded a similar result. The prevalence of each comorbidity at the index date, the cumulative incidence at 10 years, and the hazard ratio (HR) of each comorbidity comparing cases with sarcoidosis and comparators without sarcoidosis are given in Table 2 .
Prevalence and Incidence of Multimorbidity
The prevalence of multimorbidity (ie, the presence of !2 chronic conditions) was similar between the 2 groups: 111 of 345 cases (32.2%) and 110 of 345 comparators (31.9%) (P¼.99). The mean number of comorbidities at the incidence/index date was 1.2 in both groups. After the index date, 156 cases (43.8%) and 142 comparators (41.2%) developed multimorbidity, corresponding to an HR of 1.60 (95% CI, 1.27-2.01; P<.001). The cumulative incidence of the presence of !3, 4, and 5 chronic conditions was also consistently significantly higher in cases. Further adjustment for baseline smoking status and obesity yielded a similar result, although statistical significance was not achieved for the presence of !3 and 4 chronic conditions ( Table 2 ). The cumulative probability of the presence of !2, 3, 4, and 5 chronic conditions over time (inclusive of the probability at the index date) for cases and comparators is displayed in Figure 1 .
Analysis by Time From the Index Date
Analysis by time from the index date was performed using 5 years of follow-up after the index date as the cutoff point. The HRs comparing cases with sarcoidosis with comparators without sarcoidosis of almost all comorbidities (except for diabetes mellitus) were numerically higher for the events that occurred within the first 5 years than those that occurred after 5 years. Similarly, analysis of multimorbidity revealed a higher HR for multimorbidity that occurred within the first 5 years (HR, 2.44; 95% CI, 1.58-3.78) than that which occurred after 5 years (HR, 1.34; 95% CI, 1.01-1.77) as presented in Table 3 .
Combination of Comorbidities
The most common combinations of conditions were hypertension-hyperlipidemia, hyperlipidemia-arthritis, and hypertensionarthritis for both patients with sarcoidosis and comparators without sarcoidosis. There is no significant difference in the frequency of the co-occurrence of any combinations of conditions between cases and comparators ( Figure 2 ).
Sensitivity Analysis
A sensitivity analysis including only 184 cases and 184 comparators with the incidence/index date on or after January 1, 1995, was performed as the diagnostic codes in the REP medical record linkage system were coded only yearly before 1994, which may have led to underrecognition or a delay in capture of comorbidities with onset before 1994. The cumulative incidence of some of the comorbidities was higher in both groups (data not shown). The relative risk comparisons between the 2 groups were similar to those in the complete analysis, although statistical power was limited by the smaller sample size (Supplemental Table, available online at http:// www.mayoclinicproceedings.org).
DISCUSSION
Multimorbidity has important clinical implications for patient well-being and survivorship and is associated with increased mortality. 18 It also has a substantial effect on health care utilization and health economics. For instance, the per capita Medicare expenditures was increased by approximately 10-fold in a Patients diagnosed with a chronic condition before the index date were excluded from its analysis. For the analyses of multiple chronic conditions, those who were diagnosed with the specified number of chronic conditions before the index date were excluded from the analyses but those with fewer chronic conditions were included, as they were still at risk of developing the specified number of comorbidities during follow-up.
beneficiaries with multimorbidity compared with beneficiaries without multimorbidity, and 95% of Medicare expenditure was used by those with multimorbidity, although they represented only 65% of Medicare beneficiaries. 19 The present study was performed to better describe the characteristics of multimorbidity in patients with sarcoidosis. A significantly increased risk of multimorbidity was found after the diagnosis of sarcoidosis. The risk appeared to be particularly high within the first 5 years of diagnosis, suggesting an acceleration in the occurrence of comorbid conditions after the occurrence of sarcoidosis. The pattern of cooccurrence of comorbidities was similar between the 2 groups.
There are several possible explanations for the observed increased multimorbidity risk. First, patients with sarcoidosis have increased inflammatory burden and chronic inflammation is linked to an increased risk of several atherosclerotic cardiovascular comorbidities including CAD, CHF, arrhythmia, and stroke. [3] [4] [5] [6] [20] [21] [22] Although not specifically studied in sarcoidosis, several inflammatory cytokines, such as interleukin 1 and tumor necrosis factor, have been shown to accelerate the atherogenic process through a number of mechanisms including vascular adhesion molecule 1, leukocyte, and matrix metalloproteinase activation. 23, 24 Chronic inflammation has also been linked to insulin resistance, 25 driving several metabolic comorbidities, including diabetes mellitus, hyperlipidemia, and hypertension. 26 Analysis by time from the diagnosis of sarcoidosis revealed that the risk of these comorbid conditions was higher within the first 5 years of diagnosis, which may further support increased inflammatory burden during this period as an explanation for these comorbidities, as patients with sarcoidosis often achieve remission/radiological improvement within the first few years. 27, 28 Second, the increased incidence of comorbidity and multimorbidity could be a complication of glucocorticoids, the most commonly used medications for the treatment of sarcoidosis. 29, 30 Several comorbidities analyzed in this study, including diabetes mellitus, hypertension, depression, and osteoporotic fracture, are well-established complications of glucocorticoids. 31 In addition, recent studies have suggested an association between the use of glucocorticoids and the increased risk of cardiovascular diseases (CAD, stroke, and CHF). 32, 33 Analysis by time from the diagnosis of sarcoidosis may further support this explanation as the risk was higher within the first 5 years of diagnosis, which was the time that most exposure to glucocorticoids occurred. Still, it is unlikely that the use of glucocorticoids was the primary reason for increased multimorbidity, as only about one-third of patients in this cohort were exposed to glucocorticoids (and less than a quarter were exposed to high-dose glucocorticoids for >90 days).
Third, the increased risk of developing one of these comorbidities could be a result of shared predisposing factors for both sarcoidosis and comorbidities. Obesity is a well-recognized risk factor for almost all comorbidities included in this study, particularly cardiovascular diseases, diabetes mellitus, hyperlipidemia, and hypertension. 34 Interestingly, obesity has been found to be a risk factor for sarcoidosis in a large cohort study of African American women 35 and a higher prevalence of obesity in patients with sarcoidosis than in comparators was observed in this cohort. 36 Fourth, the apparent increased incidence of multimorbidity could be a result of surveillance bias, as patients with sarcoidosis may have more medical examinations and laboratory investigations because of their sarcoidosis. Nonetheless, analysis by time from sarcoidosis diagnosis continued to reveal a significantly increased risk of multimorbidity after 5 years of diagnosis, which may suggest that surveillance bias did not play a substantial role.
The major strength of this study is its population-based methodology with verification of sarcoidosis and selected comorbidities by individual medical record review. Thus, the accuracy of diagnosis was high and the risk of misclassification was minimized. Moreover, the comprehensive resources of the REP facilitated a virtually complete identification of all clinically recognized cases of sarcoidosis in the community and minimized the likelihood of selection bias of only more severe cases, a common concern of studies using referral-based cohorts. The duration of follow-up in this study was long (median length of follow-up of at least 13 years for both cases and comparators), which allowed analysis of trend and accumulation of comorbidities over time.
The study has some limitations that are inherent to its retrospective nature as medical information was obtained and recorded at the discretion of the physicians who saw the patients without a specific protocol. Therefore, some pertinent information may not be available. Some of the studied comorbidities such as asthma were code based and not verified by individual medical record review, which may lower the accuracy of diagnosis. Identification of the exact time point of the onset of comorbidities could be imprecise, especially before 1994 when diagnoses were coded only once a year. Comorbidities are reported additively in this and other studies of multimorbidity, and no attempt was made to weight the relative influence of each comorbidity. Last, because the epidemiology and clinical phenotypes of sarcoidosis vary across different ethnic groups, 37 ,38 generalizability of the observations from this study may be limited, as the population of Olmsted County is predominantly of Northern European ancestry. Moreover, there is a higher proportion of workers in the health care industry who may have different patterns of utilization of health care resources.
CONCLUSION
This first-ever population-based assessment of multimorbidity in patients with sarcoidosis revealed that these patients have a significantly higher risk of developing multimorbidity compared with sex-and age-matched individuals without sarcoidosis. Patients with sarcoidosis are at higher risk of several individual comorbidities related to the disease and its treatment, including some cardiovascular diseases, arthritis, depression, and diabetes mellitus. These findings reflect the increased health care burden of sarcoidosis and are a reference point for patient management and health care policy. The shading from light to dark indicates increasing absolute frequency of each combination. There is no significant difference in the frequency of the co-occurrence of any combinations of conditions between cases and comparators. CAD ¼ coronary artery disease; CHF ¼ congestive heart failure; CKD ¼ chronic kidney disease; COPD ¼ chronic obstructive pulmonary disease.
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